Hanmi Pharmaceutical

Novo Nordisk raises 2026 guidance amid GLP-1 growth

114 clusters · 554 sources · last updated 2 days ago

Latest: Novo Nordisk raises 2026 outlook as Wegovy pill sales exceed expectations

Novo Nordisk is navigating market volatility and patent risks, specifically the potential for generic competition as U.S. patents for its primary active ingredients expire in 2032. While the company faces intense competi

South Korea advances sovereign AI and specialized AI agents

35 clusters · 68 sources · last updated 3 days ago

Latest: South Korea announces major AI investment and autonomous shipping strategy

In late 2026, South Korea accelerated its push for sovereign AI and specialized agents across public, financial, and maritime sectors. Building on the ‘AI for All Project’ and the October 2026 formation of a ‘Sovereign A

Hanmi Pharmaceutical obesity drug Epe/Effe launch

5 clusters · 12 sources · last updated 5 days ago

Latest: Hanmi Pharm launches domestic obesity drug Epe in South Korea

Hanmi Pharmaceutical has initiated the commercialization of ‘Epe’ (also referred to as ‘Effe’), South Korea’s first domestically developed GLP-1 class obesity medication. Following the initial product shipment on October

BIX 2026 biotechnology convention in Seoul

3 clusters · 7 sources · last updated 9 days ago

Latest: BIX 2026 conference explores AI, biotech, and space medicine

The BIOPLUS-INTERPHEX KOREA 2026 (BIX 2026) convention is scheduled to be held from October 28 to 30 at the COEX convention center in Seoul, South Korea. Organized by the Korea Biotechnology Industry Organization, the ev

South Korean biotechnology industry expansion

4 clusters · 8 sources · last updated 15 days ago

Latest: Samsung Biologics and Daeduck Electronics report strong growth

South Korean pharmaceutical companies are transitioning from technology followers to global leaders through the development of blockbuster drugs and significant international acquisitions. Projections from the Korea Hea